Bortezomib in Treating Young Patients With Refractory or Recurrent Leukemia

Recurrent Childhood Acute Lymphoblastic Leukemia Clinical Trial

Official title:

A Phase I Study of PS-341 (Velcade, Bortezomib) in Pediatric Patients With Refractory/Recurrent Leukemias

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00077467
• Other study ID #: NCI-2012-01809
• Secondary ID: ADVL0317CDR00003
• Status: Completed
• Phase: Phase 1
• First received: February 10, 2004
• Last updated: June 4, 2013
• Start date: January 2004

Study information

• Verified date: June 2013
• Source: National Cancer Institute (NCI)
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This phase I trial is studying the side effects and best dose of bortezomib in treating young patients with refractory or recurrent leukemia. Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary for their growth.

Description:

OBJECTIVES: Primary I. Determine the maximum tolerated dose and recommended phase II dose of bortezomib in children with refractory or recurrent leukemia.

II. Determine the toxic effects of this drug in these patients. III. Determine the pharmacokinetics of this drug in these patients.

Secondary I. Determine, preliminarily, the antitumor activity of this drug in these patients.

II. Determine, preliminarily, the biologic activity of this drug in these patients.

OUTLINE: This is a dose-escalation, open-label, multicenter study.

Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of bortezomib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.

PROJECTED ACCRUAL: A total of 3-36 patients will be accrued for this study within 1.5-36 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. primary completion date: March 2006
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 1 Year to 21 Years

Eligibility

Inclusion Criteria:

• Histologically confirmed leukemia of 1 of the following types:

• Acute lymphoblastic leukemia

• Acute myeloid leukemia

• Chronic myelogenous leukemia in blast crisis

• Relapsed or refractory disease

• Immunophenotypically confirmed disease, either at initial diagnosis or relapse

• More than 25% blasts in the bone marrow (M3 bone marrow)

• Active extramedullary disease (except leptomeningeal disease) allowed

• No known curative therapy or therapy proven to prolong survival with an acceptable quality of life available

• Performance status - Karnofsky 50-100% (for patients age 11 to 21)

• Performance status - Lansky 50-100% (for patients age 10 and under)

• Platelet count = 20,000/mm^3*

• Hemoglobin = 8.0 g/dL*

• WBC < 20,000/mm^3** (hydroxyurea for cytoreduction allowed)

• No hyperleukocytosis (i.e., WBC > 100,000/mm^3)

• Bilirubin = 1.5 times upper limit of normal (ULN)

• ALT = 5 times ULN

• Albumin = 2 g/dL

• Creatinine clearance or radioisotope glomerular filtration rate = 70 mL/min

• Creatinine based on age as follows:

• = 0.8 mg/dL for patients age 5 and under

• = 1.0 mg/dL for patients age 6 to 10

• = 1.2 mg/dL for patients age 11 to 15

• = 1.5 mg/dL for patients age 16 to 21

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

• No uncontrolled infection

• Recovered from prior immunotherapy

• At least 7 days since prior filgrastim (G-CSF) or sargramostim (GM-CSF)

• At least 7 days since prior biologic agents

• At least 3 months since prior stem cell transplantation or rescue and no evidence of active graft-versus-host disease

• No concurrent prophylactic G-CSF during course 1 of study

• No concurrent immunotherapy

• No concurrent biologic therapy

• Recovered from prior chemotherapy

• At least 24 hours since prior hydroxyurea for cytoreduction

• At least 6 weeks since prior nitrosoureas

• No concurrent chemotherapy

• At least 7 days since prior steroids (except as premedication prior to blood product transfusion)

• Recovered from prior radiotherapy

• At least 2 weeks since prior small port local palliative radiotherapy

• At least 3 months since prior total body irradiation, craniospinal irradiation, or irradiation to more than 50% of the pelvis

• At least 6 weeks since other prior substantial bone marrow radiotherapy

• No concurrent radiotherapy

• At least 7 days since prior retinoids

• No other concurrent investigational agents

• No other concurrent anticancer agents

• No concurrent anticonvulsant medications known to activate the cytochrome p450 system (e.g., phenytoin, carbamazepine, or phenobarbital)

• Concurrent benzodiazepines and gabapentin are allowed

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Blast Crisis
• Blastic Phase Chronic Myelogenous Leukemia
• Childhood Acute Promyelocytic Leukemia (M3)
• Leukemia
• Leukemia, Lymphoid
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute
• Leukemia, Promyelocytic, Acute
• Precursor Cell Lymphoblastic Leukemia-Lymphoma
• Recurrent Childhood Acute Lymphoblastic Leukemia
• Recurrent Childhood Acute Myeloid Leukemia

Intervention

Drug:
• bortezomib
Given IV

Other:
• pharmacological study
Correlative studies
• laboratory biomarker analysis
Correlative studies

Locations

Country	Name	City	State
United States	COG Phase I Consortium	Arcadia	California

Sponsors (1)

Lead Sponsor	Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum tolerated dose and recommended phase II dose		Up to 21 days	Yes
Primary	Toxicity as assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) 3.0		Up to 2 years	Yes
Primary	Pharmacokinetics as assessed by confidence intervals (CI), area under the curve (AUC), and half-life (T ½)		Pretreatment, days 1, 8, 18-22 of course 1	No
Secondary	Antitumor activity		Up to 2 years	No
Secondary	Correlate apoptosis and NF-kB activation		Prestudy, days 8 and 18	No